Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,147
archived clinical trials in
Asthma

Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients With Asthma (CPAP)
Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients With Asthma
Status: Enrolling
Updated:  8/17/2015
University of Virginia
mi
from
Charlottesville, VA
Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients With Asthma (CPAP)
Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients With Asthma
Status: Enrolling
Updated: 8/17/2015
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients With Asthma (CPAP)
Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients With Asthma
Status: Enrolling
Updated:  8/17/2015
University of California, San Diego
mi
from
San Diego, CA
Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients With Asthma (CPAP)
Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients With Asthma
Status: Enrolling
Updated: 8/17/2015
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Talking Card for Asthma
The Talking Card for Asthma: A Recordable Audio Discharge Instruction Device to Improve Asthma Control
Status: Enrolling
Updated:  8/20/2015
University of South Florida
mi
from
Tampa, FL
Talking Card for Asthma
The Talking Card for Asthma: A Recordable Audio Discharge Instruction Device to Improve Asthma Control
Status: Enrolling
Updated: 8/20/2015
University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Talking Card for Asthma
The Talking Card for Asthma: A Recordable Audio Discharge Instruction Device to Improve Asthma Control
Status: Enrolling
Updated:  8/20/2015
Children's Mercy Hospital
mi
from
Kansas City, MO
Talking Card for Asthma
The Talking Card for Asthma: A Recordable Audio Discharge Instruction Device to Improve Asthma Control
Status: Enrolling
Updated: 8/20/2015
Children's Mercy Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
Improving Asthma Outcomes in an Urban Pediatric Population
Improving Asthma Outcomes in a High Morbidity Urban Pediatric Population: an Emergency Department-based Randomized Clinical Trial
Status: Enrolling
Updated:  8/21/2015
Childrens National Medical Center
mi
from
Washington,
Improving Asthma Outcomes in an Urban Pediatric Population
Improving Asthma Outcomes in a High Morbidity Urban Pediatric Population: an Emergency Department-based Randomized Clinical Trial
Status: Enrolling
Updated: 8/21/2015
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Involving Community Pharmacies in Improving Asthma Outcomes in an Urban Pediatric Population
Improving Pediatric Asthma Care in the District of Columbia (IMPACT DC)-Community Pharmacy Intervention
Status: Enrolling
Updated:  8/21/2015
Childrens National Medical Center
mi
from
Washington,
Involving Community Pharmacies in Improving Asthma Outcomes in an Urban Pediatric Population
Improving Pediatric Asthma Care in the District of Columbia (IMPACT DC)-Community Pharmacy Intervention
Status: Enrolling
Updated: 8/21/2015
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Pediatric Asthma Alert Intervention for Minority Children With Asthma
Pediatric Asthma Alert Intervention for Minority Children
Status: Enrolling
Updated:  8/31/2015
Johns Hopkins University
mi
from
Baltimore, MD
Pediatric Asthma Alert Intervention for Minority Children With Asthma
Pediatric Asthma Alert Intervention for Minority Children
Status: Enrolling
Updated: 8/31/2015
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
The Effects of Broccoli Sprout Extract on Obstructive Lung Disease
Status: Enrolling
Updated:  8/31/2015
Johns Hopkins Medical Institutions
mi
from
Baltimore, MD
The Effects of Broccoli Sprout Extract on Obstructive Lung Disease
Status: Enrolling
Updated: 8/31/2015
Johns Hopkins Medical Institutions
mi
from
Baltimore, MD
Click here to add this to my saved trials
Particulate Reduction Education in City Homes
Particulate Reduction Education in City Homes (PREACH)
Status: Enrolling
Updated:  8/31/2015
Johns Hopkins University
mi
from
Baltimore, MD
Particulate Reduction Education in City Homes
Particulate Reduction Education in City Homes (PREACH)
Status: Enrolling
Updated: 8/31/2015
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Observational Assessment of Baseline Asthma Control in African-American Children
Observational Assessment of Baseline Asthma Control as a Susceptibility Factor for Air Pollution Health Effects in African-American Children With Moderate-severe Asthma (Teen AIRE Study)
Status: Enrolling
Updated:  9/2/2015
Rex Hospital, Inc
mi
from
Raleigh, NC
Observational Assessment of Baseline Asthma Control in African-American Children
Observational Assessment of Baseline Asthma Control as a Susceptibility Factor for Air Pollution Health Effects in African-American Children With Moderate-severe Asthma (Teen AIRE Study)
Status: Enrolling
Updated: 9/2/2015
Rex Hospital, Inc
mi
from
Raleigh, NC
Click here to add this to my saved trials
Dietary Interventions in Asthma Treatment: Sprouts Study
Dietary Interventions in Asthma Treatment: Sprouts Study
Status: Enrolling
Updated:  9/5/2015
Johns Hopkins University
mi
from
Baltimore, MD
Dietary Interventions in Asthma Treatment: Sprouts Study
Dietary Interventions in Asthma Treatment: Sprouts Study
Status: Enrolling
Updated: 9/5/2015
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Effects of Whole Sprouts on Upper Airway Allergic Inflammation
Dietary Interventions and Asthma Treatment: A Pilot Study of the Effects of Whole Sprouts on Upper Airway Allergic Inflammation
Status: Enrolling
Updated:  9/5/2015
Johns Hopkins Hospital
mi
from
Baltimore, MD
Effects of Whole Sprouts on Upper Airway Allergic Inflammation
Dietary Interventions and Asthma Treatment: A Pilot Study of the Effects of Whole Sprouts on Upper Airway Allergic Inflammation
Status: Enrolling
Updated: 9/5/2015
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment
The Effect of Beta-2 Adrenergic Polymorphisms on the Bronchoprotective Effects of Regular Salmeterol Treatment in Asthma
Status: Enrolling
Updated:  9/21/2015
Brigham and Women's Hosp
mi
from
Boston, MA
How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment
The Effect of Beta-2 Adrenergic Polymorphisms on the Bronchoprotective Effects of Regular Salmeterol Treatment in Asthma
Status: Enrolling
Updated: 9/21/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment
The Effect of Beta-2 Adrenergic Polymorphisms on the Bronchoprotective Effects of Regular Salmeterol Treatment in Asthma
Status: Enrolling
Updated:  9/21/2015
University of Wisconsin
mi
from
Madison, WI
How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment
The Effect of Beta-2 Adrenergic Polymorphisms on the Bronchoprotective Effects of Regular Salmeterol Treatment in Asthma
Status: Enrolling
Updated: 9/21/2015
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site 043
mi
from
Scottsdale, AZ
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site 043
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site
mi
from
Los Angeles, CA
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site 10140
mi
from
Orange, CA
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site 10140
mi
from
Orange, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site
mi
from
San Diego, CA
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site 10172
mi
from
Colorado Springs, CO
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site 10172
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site 52
mi
from
Debary, FL
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site 52
mi
from
Debary, FL
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site 1345
mi
from
Miami, FL
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site 1345
mi
from
Miami, FL
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site 10525
mi
from
Valrico, FL
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site 10525
mi
from
Valrico, FL
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site 17
mi
from
Lexington, KY
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site 17
mi
from
Lexington, KY
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site
mi
from
Louisville, KY
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site 024
mi
from
Boston, MA
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site 024
mi
from
Boston, MA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site
mi
from
St. Louis, MO
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site 59
mi
from
Missoula, MT
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site 59
mi
from
Missoula, MT
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site 13258
mi
from
Boys Town, NE
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site 13258
mi
from
Boys Town, NE
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site 1369
mi
from
Bronx, NY
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site 1369
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site 10112
mi
from
Rochester, NY
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site 10112
mi
from
Rochester, NY
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site
mi
from
Winston-Salem, NC
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site
mi
from
Cincinnati, OH
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site
mi
from
Columbus, OH
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site
mi
from
Oklahoma City, OK
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site 10509
mi
from
Altoona, PA
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site 10509
mi
from
Altoona, PA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site 1310
mi
from
Nashville, TN
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site 1310
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site 10119
mi
from
Boerne, TX
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site 10119
mi
from
Boerne, TX
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site
mi
from
Houston, TX
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site 09
mi
from
Richmond, VA
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site 09
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site 77
mi
from
Madison, WI
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site 77
mi
from
Madison, WI
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated:  9/23/2015
Teva Investigational Site 643
mi
from
Nedlands,
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Status: Enrolling
Updated: 9/23/2015
Teva Investigational Site 643
mi
from
Nedlands,
Click here to add this to my saved trials
Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma
Status: Enrolling
Updated:  9/23/2015
Oriel Investigative Site
mi
from
Goodyear, AZ
Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma
Status: Enrolling
Updated: 9/23/2015
Oriel Investigative Site
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma
Status: Enrolling
Updated:  9/23/2015
Oriel Investigative Site
mi
from
Tempe, AZ
Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma
Status: Enrolling
Updated: 9/23/2015
Oriel Investigative Site
mi
from
Tempe, AZ
Click here to add this to my saved trials
Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma
Status: Enrolling
Updated:  9/23/2015
Oriel Investigative Site
mi
from
Anaheim, CA
Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma
Status: Enrolling
Updated: 9/23/2015
Oriel Investigative Site
mi
from
Anaheim, CA
Click here to add this to my saved trials
Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma
Status: Enrolling
Updated:  9/23/2015
Oriel Investigative Site
mi
from
Los Angeles, CA
Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma
Status: Enrolling
Updated: 9/23/2015
Oriel Investigative Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma
Status: Enrolling
Updated:  9/23/2015
Oriel Invetigative Site
mi
from
Los Angeles, CA
Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma
Status: Enrolling
Updated: 9/23/2015
Oriel Invetigative Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma
Status: Enrolling
Updated:  9/23/2015
Oriel Investigative Site
mi
from
Mission Viejo, CA
Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma
Status: Enrolling
Updated: 9/23/2015
Oriel Investigative Site
mi
from
Mission Viejo, CA
Click here to add this to my saved trials
Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma
Status: Enrolling
Updated:  9/23/2015
Oriel Investigative Site
mi
from
Centennial, CO
Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma
Status: Enrolling
Updated: 9/23/2015
Oriel Investigative Site
mi
from
Centennial, CO
Click here to add this to my saved trials
Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma
Status: Enrolling
Updated:  9/23/2015
Oriel Investigative Site
mi
from
Clearwater, FL
Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma
Status: Enrolling
Updated: 9/23/2015
Oriel Investigative Site
mi
from
Clearwater, FL
Click here to add this to my saved trials
Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma
Status: Enrolling
Updated:  9/23/2015
Oriel Investigative Site
mi
from
Coral Gables, FL
Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma
Status: Enrolling
Updated: 9/23/2015
Oriel Investigative Site
mi
from
Coral Gables, FL
Click here to add this to my saved trials